Grants and Contracts Details
Description
A metabolic shift favoring ceramide formation in the brain has been proposed to play an
important role in amyloid-â (Aâ) formation and neuronal death in Alzheimer’s disease (AD). However, how
neurotoxicity is mediated and whether pharmacological inhibition of ceramide generation represents a valid
approach to modify AD pathology is still uncertain. The long-term goal of this research proposal is to dissect
mitochondria dysfunction mediated by ceramide in AD and identify specific targets that protect
mitochondria homeostasis. Recently, it was demonstrated that ceramide synthesis (CerS) in mitochondria
is a key player in mitophagy and acid sphingomyelinase (A-SMase) mediates respiratory chain defects. Our
central hypothesis is that ceramide mediates neurotoxicity by affecting mitochondrial function in neurons
and that this process is prevented by inhibiting ceramide metabolism enzymes important for mitochondria
homeostasis, such as CerS and A-SMase. The specific aims that test our hypothesis are: i) Identify ceramide
species in mitochondria derived from AD mice models; ii) Examine whether extracellular trafficking of
ceramide in micro-vesicles contributes to neurotoxic signaling propagation; iii) Determine whether CerS
and/or A-SMase inhibition protects mitochondria from ceramide pore formation, lethal mitophagy, and
respiratory chain defects; and iv) Delineate whether A-SMase and/or CerS inhibition corrects cognitive
decline in an AD animal model. Transgenic mice models of familial AD (5xFAD) will be used to isolated
mitochondria from brain tissue and to prepare neuronal and astrocyte primary culture to answer aim 1, 2
and 3. In aim 2 we will employ also neuroblastoma cells to study ceramide release in micro-vesicles. Primary
outcomes of aim 1, 2 and 3 are ceramides species levels, measured by LC-MS/MS, and mitochondrial
function, assayed through Seahorse approach. Next, the 5xFAD mice model will be challenged with daily
administration of FTY720 to inhibit CerS and/or Imipramine to inhibit A-SMase for answering aim 4.
Object recognition task will be administered during the last week of treatment to assess memory. At
termination, brains will be collected for further biochemical analyses. We will measure Aâ pathology, global
ceramide pathology in different brain regions, mitochondria function and neuronal loss. Upon conclusion,
we will gain knowledge on the role of ceramide in AD pathophysiology and identify new therapeutic targets
for the treatment of AD. The proposed research is innovative because it centers on the role of ceramide in
AD pathophysiology, and findings may extend new therapeutics from AD to other neurodegenerative
diseases where ceramide metabolism is known to play a role.
Status | Finished |
---|---|
Effective start/end date | 9/1/20 → 1/31/23 |
Funding
- BrightFocus Foundation: $200,000.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.